Literature DB >> 20837753

Clarithromycin significantly increases linezolid serum concentrations.

Mathieu S Bolhuis, Richard van Altena, Donald R A Uges, Tjip S van der Werf, Jos G W Kosterink, Jan-Willem C Alffenaar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20837753      PMCID： PMC2981294          DOI： 10.1128/AAC.00757-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.

Authors:  Benjamin C Gebhart; Brian C Barker; Boaz A Markewitz
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

3.  Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

Authors:  Bent von der Lippe; Per Sandven; Oddbjørn Brubakk
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

4.  Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors:  I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

Review 5.  Linezolid: a review of safety and tolerability.

Authors:  Donald C Vinh; Ethan Rubinstein
Journal:  J Infect       Date:  2009-09       Impact factor: 6.072

6.  Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Authors:  Sonja Eberl; Bertold Renner; Antje Neubert; Mareike Reisig; Iouri Bachmakov; Jörg König; Frank Dörje; Thomas E Mürdter; Andreas Ackermann; Harald Dormann; Karl G Gassmann; Eckhart G Hahn; Stefanie Zierhut; Kay Brune; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Authors:  Jan-Willem C Alffenaar; Jos G W Kosterink; Richard van Altena; Tjip S van der Werf; Donald R A Uges; Johannes H Proost
Journal:  Ther Drug Monit       Date:  2010-02       Impact factor: 3.681

9.  Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Won-Jung Koh; O Jung Kwon; Hyesun Gwak; Joo Won Chung; Sang-Nae Cho; Woo Sung Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2009-05-25       Impact factor: 5.790
  9 in total
  10 in total

1.  Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis.

Authors:  Matthew W Carroll; Hongjo Choi; Seonyeong Min; Soohee Hwang; Hyeeun Park; Taeksun Song; Yumi Park; Han-Seung Jeon; Lisa C Goldfeder; Laura E Via; Janette Lebron; Boyoung Jin; Ying Cai; Clifton E Barry; Myungsun Lee
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

2.  Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.

Authors:  Alicia Galar; Maricela Valerio; Patricia Muñoz; Luis Alcalá; Xandra García-González; Almudena Burillo; María Sanjurjo; Santiago Grau; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Authors:  M S Bolhuis; R van Altena; K van Hateren; W C M de Lange; B Greijdanus; D R A Uges; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

4.  Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Authors:  D H Vu; M S Bolhuis; R A Koster; B Greijdanus; W C M de Lange; R van Altena; J R B J Brouwers; D R A Uges; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

5.  Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.

Authors:  Yasuhiro Horita; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

Review 6.  Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.

Authors:  Gianluca Villa; Paola Di Maggio; A Raffaele De Gaudio; Andrea Novelli; Riccardo Antoniotti; Enrico Fiaccadori; Chiara Adembri
Journal:  Crit Care       Date:  2016-11-19       Impact factor: 9.097

Review 7.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

8.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

9.  Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study.

Authors:  Jie Fang; Congqin Chen; Yan Wu; Min Zhang; Ying Zhang; Guochao Shi; Yijin Yao; Hong Chen; Xiaolan Bian
Journal:  Ann Transl Med       Date:  2020-04

10.  Medical management of atraumatic Mycobacterium abscessus cutaneous infection: A case report.

Authors:  Chong Wei Tiong; Thomas Nack; Alex Y C Tai; N Deborah Friedman
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.